He Eye Specialist Hospital
Shenyang, 110034, China
NCT Number: NCT06714994
To determine whether provision of free spectacles to rural-dwelling Chinese secondary school students with visually-significant refractive error, together with a teacher-based incentive to promote their use, increases the proportion of children going on to academic high school, as opposed to dropping out or pursuing a vocational track.
Trial opening soon.
Get Notified11 year–16 year
All sexes
Interventional
Not applicable
Shenyang, 110034, China
The investigators propose in the current trial to significantly expand the evidence base for spectacle distribution as the most-effective health intervention to improve educational opportunities for China's under-served rural children and adolescents by assessing impact on school attainment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Children will receive free spectacles
Time frame: In July following completion of Year 3 of Middle School. This occurs after 32 months of participant followup.
This will be assessed by systematically contacting parents, teachers and students to ascertain enrolment status, which REAP has used to obtain > 97% follow-up in previous studies of high school accession. In the event of inconsistent responses, priority will be given to responses of parents, then teachers and finally students
Time frame: After 12 months of participant followup
Actual presence of spectacles on the child's face (rather than having glasses at school)at the time of an unannounced examination.
Time frame: After 12 months of participant followup
Frequency of blackboard versus textbook use in the major subjects (Maths Chinese, English) on a questionnaire administered to teachers, and answered as "all", "most", "about half", little" or "none" of teaching.
Time frame: At study closeout, after 32 months of participant follow up
Calculated as ratio of incremental cost to proportion of children who continue to academic high school as opposed to vocational high school or no schooling. Incremental cost is the difference of costs between implementation of intervention and control, Intervention costs will comprise the screening test glasses (including replacements).
Time frame: At baseline and 12 months post-treatment
Depression and anxiety score measured with Anxiety Stress Scale (DASS). The score range for depression, anxiety and stress are 0-42, with higher score indicates more severe mental health problems.
Time frame: At baseline and 12 months post-treatment
Self-esteem score measured with the Rosenberg Self-esteem Scale. The scores range from 0-30, with higher scores indicate higher self-esteem.
Time frame: At baseline and 12 months post-treatment
Emotional and behavioral problems score using the Strengths and Difficulties Questionnaire (SDQ), with difficulties score ranges from 0 to 40, Prosocial scale ranges from 0-10,with higher score indicates severe mental health and behavioral problems.
Time frame: At baseline and 12 months post-treatment
Progression of Shortsightedness will be measured using change in refraction over time
Contact information is provided by the study sponsor or research team.
Guanghao Qin
CONTACT
Jiayan Chen
CONTACT
He Eye Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724210
Eye Diseases, Myopia
Beijing, Beijing Municipality, China
View Trial DetailsNCT07406906
Eye Diseases, Myopia
Hong Kong
View Trial DetailsNCT07721714
Astigmatism, Eye Diseases
Palo Alto, California, United States
View Trial DetailsNCT07696468
Eye Diseases, Myopia
Guangzhou, Guangdong, China
View Trial Details